These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21367665)

  • 1. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
    Claussen MC; Korn T
    Clin Immunol; 2012 Jan; 142(1):49-56. PubMed ID: 21367665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of multiple sclerosis and the place of teriflunomide.
    Gold R; Wolinsky JS
    Acta Neurol Scand; 2011 Aug; 124(2):75-84. PubMed ID: 20880295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
    Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for oral therapy in multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and development of new therapeutics for multiple sclerosis.
    Linker RA; Kieseier BC; Gold R
    Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for the treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS.
    Rakhila H; Rozek T; Hopkins A; Proudman S; Cleland L; James M; Wiese M
    J Pharm Biomed Anal; 2011 May; 55(2):325-31. PubMed ID: 21349677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
    Aly L; Hemmer B; Korn T
    Curr Neuropharmacol; 2017; 15(6):874-891. PubMed ID: 27928949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Teriflunomide for treatment of multiple sclerosis].
    Warnke C; Meyer Zu Hörste G; Menge T; Stüve O; Hartung HP; Wiendl H; Kieseier BC
    Nervenarzt; 2013 Jun; 84(6):724-31. PubMed ID: 23695001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry.
    Parekh JM; Vaghela RN; Sutariya DK; Sanyal M; Yadav M; Shrivastav PS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Aug; 878(24):2217-25. PubMed ID: 20643586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on teriflunomide.
    Tallantyre E; Evangelou N; Constantinescu CS
    Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
    Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K; Rózsa C; Vécsei L
    Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
    Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S
    Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.